Mukund Prasad Poudel

You are already at the latest version Pediatric acute myeloid leukemia (AML) is the second most common childhood hematologic malignancy, accounting for approximately 20% of acute leukemias in children. Although complete remission rates now approach 90% and 10-year survival exceeds 60%, relapse remains frequent and treatment-related toxicity is substantial. This narrative review provides a comprehensive overview of current treatment approaches and emerging strategies in pediatric AML.